[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vagus-nerve-stimulations\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vagus-nerve-stimulations":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,78,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100631509","acute-cardiovascular-effects-of-transcutaneous-auricular-vagus-nerve-stimulation-100631509",false,"NCT07501611","Acute Cardiovascular Effects of Transcutaneous Auricular Vagus Nerve Stimulation","Inclusion Criteria:\n\nParticipants will be eligible if they meet the following criteria:\n\n* Age: 18-45 years\n* Healthy status: No diagnosed cardiovascular, metabolic, neurological, or psychiatric conditions\n* BP: Normotensive (office SBP \\\u003C140 mmHg and DBP \\\u003C90 mmHg)\n* Body Mass Index (BMI): 18.5-30 kg\u002Fm²Non-smoker or light smoker (≤5 cigarettes per day, willing to abstain before testing)\n* Ability to understand and provide written informed consent\n* Willingness to comply with study procedures, including:\n* No regular use of medications affecting cardiovascular or autonomic function (including beta-blockers, calcium channel blockers, antihypertensives, or psychotropic medications)\n\nExclusion Criteria:\n\n* Current participation in another interventional trial\n* Clinically significant resting bradycardia (HR \\\u003C50 bpm)\n* Known damage or surgical removal of the vagus nerve\n* Established cardiovascular disease (e.g., myocardial infarction, heart failure, arrhythmias, stroke, peripheral vascular disease)\n* Diagnosed with hypertension or currently taking antihypertensive medication\n* Known diagnosis of trigeminal neuralgia or other chronic pain conditions\n* Active ear infection or skin conditions affecting the tragus\u002Fauricle\n* Implanted electronic devices (pacemaker, defibrillator, vagal nerve stimulator)\n* Pregnancy or breastfeeding\n* Current diagnosis of anxiety, depression, or other psychiatric conditions requiring medication\n* History of syncope or severe vasovagal response",true,"ALL","18 Years","45 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","Introduction\n\nCardiovascular disease (CVD) remains the leading cause of mortality worldwide, with arterial hypertension representing the most significant modifiable risk factor (Lim et al., 2012; Mills et al., 2020). While clinical manifestations of arterial hypertension typically emerge in later life, the underlying pathophysiological mechanisms, particularly autonomic dysfunction, begin decades earlier.\n\nAutonomic imbalance, characterised by sympathetic overactivity and diminished parasympathetic tone, not only precedes sustained arterial hypertension but also independently predicts future cardiovascular risk, even in normotensive individuals (He et al., 2023; Thayer et al., 2010). Reduced heart rate variability (HRV), a non-invasive marker of parasympathetic activity, has been consistently associated with increased cardiovascular morbidity across diverse populations (Task Force, 1996).\n\nCritically, young apparently healthy adults with suboptimal lifestyle factors, including physical inactivity, poor dietary habits, and chronic stress, frequently exhibit reduced HRV and altered sympathovagal balance (Liao et al., 1998). These subclinical autonomic changes represent an early, potentially reversible stage in the cardiovascular disease continuum, suggesting that interventions targeting autonomic balance may prevent or delay progression to overt disease (Goldstein et al., 2011).\n\nThe vagus nerve, the main parasympathetic pathway, exerts multiple cardioprotective effects, including heart rate deceleration, baroreflex enhancement, reduced vascular tone, and anti-inflammatory activity (Thayer \\& Sternberg, 2006). Transcutaneous auricular vagus nerve stimulation (taVNS) has emerged as a non-invasive method to enhance vagal activity by delivering electrical stimulation to the auricular branch of the vagus nerve via surface electrodes placed on the tragus or cymba conchae (Badran et al., 2018). Neuroimaging studies confirm that taVNS activates central vagal projections, including the nucleus tractus solitarius, the primary relay station for cardiovascular autonomic control (Frangos et al., 2015).\n\nPreliminary research demonstrates that acute taVNS sessions increase HRV, enhance baroreflex sensitivity, and reduce sympathetic vascular tone in healthy adults (Clancy et al., 2014; De Couck et al., 2017), while emerging evidence suggests clinically meaningful reductions in blood pressure (BP) in hypertensive patients (Mbikyo et al., 2024).\n\nDespite these promising findings, significant knowledge gaps remain. Most studies have examined clinical populations with pre-existing autonomic abnormalities, making it difficult to isolate primary taVNS mechanisms from disease-related compensatory responses. Additionally, chronic intervention protocols preclude detailed characterisation of immediate autonomic and hemodynamic changes. Conducting mechanistic studies in healthy populations offers critical advantages: absence of confounding medications and disease adaptations enables clearer identification of taVNS-induced autonomic and hemodynamic changes, while establishing baseline response patterns provides an essential reference framework for interpreting clinical population responses and informing preventive interventions. Investigation of acute responses permits precise temporal mapping of physiological changes, distinguishing primary mechanisms from downstream consequences, enables efficient optimisation of stimulation parameters, and provides biological plausibility for chronic effects while identifying potential responders to therapy.\n\nTherefore, this study proposes a randomised, sham-controlled crossover study to systematically characterise acute cardiovascular and autonomic responses to a single 60-minute taVNS session in healthy young adults. Using continuous non-invasive BP monitoring and detailed HRV analysis, this study will establish whether taVNS produces acute, measurable changes in BP, heart rate, and autonomic balance in individuals with normal baseline function. We will elucidate the temporal dynamics of taVNS-induced effects, characterise the mechanistic pathways distinguishing cardiac, hemodynamic, and autonomic contributions, and evaluate the specificity of active stimulation versus sham conditions. By establishing baseline physiological response patterns and elucidating acute mechanisms in a well-controlled population, our findings will lay the groundwork for subsequent investigations in at-risk and hypertensive individuals, ultimately contributing to evidence-based, personalised autonomic modulation therapy for cardiovascular disease prevention and management.",[27],"Vagus Nerve Stimulations",[29,30],"blood pressure","heart rate variability","NOT_YET_RECRUITING","2026-03-24",{"date":34,"type":35},"2026-03-30","ACTUAL",{"date":37,"type":21},"2026-03-01",{"date":39,"type":21},"2027-12-01",{"name":41,"class":42},"Northumbria University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":43},"100630073","transcutaneous-auricular-vagus-nerve-stimulation-and-spirometry-sham-controlled-randomized-trial-100630073","NCT07482930","Transcutaneous Auricular Vagus Nerve Stimulation and Spirometry: Sham-Controlled Randomized Trial","Acute Effects Transcutaneous Auricular Vagus Nerve Stimulation on Spirometric Parameters in Healthy Individuals: A Sham-Controlled Randomized Study","taVNS-SPIRO","Inclusion Criteria:\n\n* Aged 18-40 years.\n* Healthy volunteers.\n* Able to perform spirometry and follow study instructions.\n* Provided written informed consent.\n\nExclusion Criteria:\n\n* Any cardiovascular disease, cardiac arrhythmia, hypertension, or related condition.\n* Any neurological disorder (e.g., diabetes mellitus, peripheral neuropathy, epilepsy).\n* Any diagnosed psychiatric disorder.\n* Any respiratory disease (e.g., asthma, chronic obstructive pulmonary disease).\n* Pregnancy or suspected pregnancy.\n* Ear conditions that prevent stimulation (infection, open wound, pain\u002Ftenderness) or presence of a piercing at\u002Fnear the stimulation site.\n* Vigorous exercise within 24 hours prior to measurement.\n* Caffeine intake, smoking, or alcohol consumption within 4-6 hours prior to measurement.\n* Marked intolerance or hypersensitivity to the device or the procedure.\n* Inability to follow instructions during measurements or refusal to complete the session.","40 Years",{"count":54,"type":21},50,[24],"This study will examine the short-term effects of transcutaneous auricular vagus nerve stimulation (a non-invasive electrical stimulation delivered through the outer ear) on lung function measured by spirometry in healthy adults. The vagus nerve is involved in many automatic body functions, and ear-based stimulation has been used in research to explore its possible effects on different physiological systems. However, it is not clear whether a brief stimulation session can acutely influence breathing test results in people without respiratory disease.\n\nHealthy volunteers aged 18-40 will take part in one laboratory visit. Participants will be randomly assigned to one of two groups: (1) active bilateral stimulation applied to specific ear regions that are known to be innervated by the vagus nerve, or (2) sham stimulation using the same device setup but designed to minimize vagal activation. The stimulation session will last approximately 10 minutes. Before and after the stimulation, participants will perform standard spirometry (breathing) tests. Primary spirometric outcomes will include common measures of lung function such as forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and peak expiratory flow (PEF). Heart rate, heart rate variability, and blood pressure may also be recorded to monitor physiological responses and safety during the visit.\n\nParticipation is voluntary and participants may withdraw at any time. The procedure is considered minimal risk. Possible side effects are usually mild and temporary, such as tingling, warmth, or mild discomfort at the ear. Rarely, participants may feel lightheaded; if this occurs, the procedure will be stopped and the participant will be monitored until symptoms resolve. There is no guaranteed direct benefit to participants. The results may help clarify whether short-term ear-based vagus nerve stimulation can influence spirometric parameters and may inform future studies on autonomic and respiratory interactions.",[27,58,59,60,61],"Spirometry","Autonomic Nervous System (ANS) Functioning and Mood State","Blood Pressure Monitoring","Respiratory Function Tests",[63,64,65,66,67,29],"transcutaneous auricular vagus nerve stimulation","spirometry","autonomic nervous system","sham stimulation","pulmonary function test","RECRUITING","2026-03-16",{"date":71,"type":35},"2026-03-19",{"date":73,"type":35},"2026-03-17",{"date":75,"type":21},"2026-04-25",{"name":77,"class":42},"SEFA HAKTAN HATIK",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":43},"100629777","efficacy-and-safety-of-transcutaneous-auricular-vagus-nerve-stimulation-for-postoperative-headache-following-stent-assisted-coiling-of-unruptured-intracranial-aneurysms-100629777","NCT07479082","Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Postoperative Headache Following Stent-Assisted Coiling of Unruptured Intracranial Aneurysms","IMPACT-HT","Inclusion Criteria:\n\n1. Age 18-80 years\n2. Diagnosed with unruptured intracranial aneurysm confirmed by imaging\n3. Planned to undergo stent-assisted coiling or flow diverter embolization\n4. Signed informed consent\n\nExclusion Criteria:\n\n1. History of SAH, ICH, brain tumor, major trauma, substance abuse, syncope, or seizures\n2. Recurrent\u002Ftraumatic\u002Finfectious\u002Fmyxomatous aneurysms\n3. Primary headache disorders (e.g., migraine, cluster headache, trigeminal neuralgia) not attributed to UIA\n4. Previous vagotomy, migraine surgery, or implanted neurostimulators\n5. Other concurrent electronic\u002Fimplantable devices (e.g., pacemakers, neurostimulators)\n6. Clinically significant hypotension, congenital heart disease, severe arrhythmia, unstable angina, or recent MI\n7. Inability to follow up due to severe psychiatric disorder or refusal\n8. Skin lesions at taVNS placement site\n9. Pregnant or lactating\n10. Participation in other trials","80 Years",{"count":87,"type":21},440,[24],"The goal of this clinical trial is to evaluate the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) in reducing postoperative headache among adults undergoing stent-assisted coiling for unruptured intracranial aneurysms (UIAs). The study will include male and female participants aged 18 to 80 years who are scheduled for endovascular treatment of UIAs with stent-assisted coiling or flow diverter devices.\n\nThe main questions it aims to answer are:\n\n* Can taVNS reduce the incidence of headache within 90 days after stent-assisted embolization of UIAs?\n* Is taVNS safe and well-tolerated in this patient population? Researchers will compare patients receiving active taVNS to those receiving sham stimulation to determine if taVNS leads to fewer postoperative headaches and reduced need for analgesic medications.\n\nParticipants will:\n\n* Wear a taVNS device on the left earlobe (active group) or cymba conchae (sham group) starting 1 day before the procedure\n* Receive 30-minute stimulation sessions, twice daily, until postoperative day 5\n* Undergo follow-up assessments of headache occurrence, pain intensity, analgesic use, and any adverse events through day 90 after the procedure",[91,92,27],"Unruptured Intracranial Aneurysm","Headache",[91,94,95],"Postoperative Headache","Vagus Nerve Stimulation","2026-03-13",{"date":98,"type":35},"2026-03-18",{"date":100,"type":35},"2025-09-30",{"date":102,"type":21},"2027-07",{"name":104,"class":42},"Beijing Tiantan Hospital",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":43},"100567415","pain-perception-and-the-autonomic-nervous-system-100567415","NCT06667895","Pain Perception and the Autonomic Nervous System","Influences of the Autonomic Nervous System on Experimental Pain Sensitization","Inclusion Criteria:\n\n1. Over 18 and below 40 years of age\n2. Good general health\n3. Able to give informed consent\n\nExclusion Criteria:\n\n1. Any major medical or psychiatric condition (e.g. heart disease, diabetes, autoimmune disorders, infectious diseases, major depressive disorder), any chronic pain condition, any respiratory problems, any acute pain at time of study\n2. Inability to follow study instructions, e.g. due to language problems\n3. Pregnancy (female participants will be asked if pregnancy could be possible)\n4. Increased alcohol (\\>2 (for women)\u002F4 (for men) standard glasses per day or \\>5 (for women)\u002F4 (for men) glasses at least once a month within a few hours) or caffeine consumption (≥ 400mg per day)\n5. Consumption of alcohol, drugs, analgesics within the last 24 h\n6. Consumption of more than 100 mg of caffeine within the last 8 h\n7. Scar tissue or generally reduced sensitivity in the designated testing site areas\n8. Shoe size \\< 38 (if experiment is conducted at the feet)\n9. History of cardiovascular disease or carotid artery disease\n10. Medication or Substances inferring with the autonomic nervous system or with pain sensitivity (e.g. Benzodiazepines, Nicotine)",{"count":113,"type":21},146,[24],"In this study, we want to investigate how pain processing and sensation are related to a certain part of the nervous system, the so-called autonomic nervous system.\n\nFor this purpose, we apply heat and pressure stimuli to the skin and test pain processing by means of ratings scales and sensory tests. Breathing, heart rate and sweat response are also measured. To assess the spinal cord level, we measure muscle response (measured by electromyography, EMG) to electrical stimulation. Additionally, sensory nerves will be stimulated at the ear and participants will also be given various questionnaires to complete.",[117,118,119,120,27],"Autonomic Nervous System Modulation","Pain Perception","Pain Sensitivity","Central Sensitization","2024-10-30",{"date":123,"type":35},"2024-10-31",{"date":125,"type":21},"2024-11-04",{"date":127,"type":21},"2026-08",{"name":129,"class":42},"Schweinhardt Petra"]